This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hochman, J. S. Search for Related Content PubMed PubMed Citation Articles by Hochman, J. S. Related Collections Acute myocardial infarction Catheter-based coronary and valvular interventions: other

(Circulation. 2003;107:2998.)
© 2003 American Heart Association, Inc.

Clinician Update

Cardiogenic Shock Complicating Acute Myocardial Infarction

Expanding the Paradigm

Judith S. Hochman, MD

From the Division of Cardiology, New York University School of Medicine, New York.

Correspondence to Judith S. Hochman, MD, New York University School of Medicine, 550 First Ave, OBV-A632, New York, NY 10016-9196. E-mail judith.hochman{at}med.nyu.edu

	Introduction

Top Introduction Classic Shock Paradigm Observations That Challenge the... A New Paradigm Effects of High Levels... Beneficial Effects of Inhibiting... Current Recommendations References

 
Cardiogenic shock (CS) is the leading cause of death for patients with acute myocardial infarction (MI) who reach the hospital alive. Its incidence has remained constant for 20 years.^1,2 Rapidly re-establishing infarct-related artery (IRA) blood flow is essential in the management of patients with shock due to right ventricular or left ventricular (LV) failure. A strategy of early revascularization is superior to initial aggressive medical therapy.^3–5 Despite the advantages of early percutaneous coronary intervention (PCI) or coronary artery bypass graft surgery (CABG), once shock is diagnosed, the mortality rate remains high (50%) despite intervention, and half of the deaths occur within the first 48 hours.^6–8 This may be caused by irreversible extensive myocardial or vital-organ damage. New evidence suggests, however, that a systemic inflammatory response, complement activation, release of inflammatory cytokines, expression of inducible nitric oxide (NO) synthase (iNOS), and inappropriate vasodilation may play an important role not only in the genesis of shock but also in outcome after shock. New insights and therapies are needed.

	Classic Shock Paradigm

Top Introduction Classic Shock Paradigm Observations That Challenge the... A New Paradigm Effects of High Levels... Beneficial Effects of Inhibiting... Current Recommendations References

 
The underlying pathophysiology of CS is profound depression of myocardial contractility, resulting in a vicious spiral of reduced cardiac output (CO), low blood pressure, further coronary insufficiency, and further reduction in contractility and CO. The classic paradigm predicts that compensatory systemic vasoconstriction with high systemic vascular resistance (SVR) should occur in response to the depression of CO (Figure 1).⁹

View larger version (28K): [in this window] [in a new window]   Figure 1. Classic shock paradigm, as illustrated by S. Hollenberg, is shown in black. The influence of the inflammatory response syndrome initiated by a large MI is illustrated in red. LVEDP indicates left ventricular end-diastolic pressure. Reprinted with permission from Harrison’s Principles of Internal Medicine.9

Autopsy studies have shown that the pathological basis of CS is extensive MI. Varying pathological stages of infarction confirm the stuttering and progressive nature of the myocardial necrosis as a corollary of the vicious spiral. Combined new and old infarctions consistently involve at least 40% of the LV myocardium in these autopsy specimens.¹⁰

	Observations That Challenge the Classic Paradigm

Top Introduction Classic Shock Paradigm Observations That Challenge the... A New Paradigm Effects of High Levels... Beneficial Effects of Inhibiting... Current Recommendations References

 
There are several observations derived from the SHOCK (SHould we emergently revascularize Occluded Coronaries in cardiogenic shocK?) trial and registry about patients with CS due to LV failure not easily explainable by our traditional concepts. These include the following:

• Average LV ejection fraction (EF) is only moderately severely depressed (30%), with a wide range of EFs and LV sizes noted.
  
• SVR on vasopressors is not elevated on average, with a very wide range of SVRs measured.
  
• A clinically evident systemic inflammatory response syndrome is often present in patients with CS.
  
• Most survivors have class I congestive heart failure (CHF) status.
  

Surprisingly, an average EF of 30% was observed in left ventriculograms and echocardiograms obtained soon after shock diagnosis in patients with confirmed shock in the SHOCK trial.^3,11 Although LV performance was measured most often on inotropic and intra-aortic balloon counterpulsation support, both of which increase EF, the hemodynamic measurements obtained concurrently document persistent hypotension, low CO, and high filling pressures.³ Patients with remote MI or dilated cardiomyopathy and mild to moderate chronic CHF often have EFs considerably lower than this and are not in shock.¹² These observations highlight the role of ventricular dilation to maintain stroke volume and peripheral vascular and neurohormonal adaptation in chronic CHF. However, an EF in the low 30s is not uncommon in uncomplicated patients with recent MI who do not have CHF.¹³

The classic notion that acute reduction in CO leads to compensatory vasoconstriction was not confirmed in many patients in the SHOCK registry and trial (Menon et al¹⁴ and Hochman et al, unpublished data, 2002). SVR varied widely but on average was not elevated at 1350 to 1400 dyne · s · cm^-5 despite vasopressor use.

Cotter et al^15,16 categorized acute heart failure patients according to cardiac power and demonstrated its importance in risk stratification and selection of therapy. Cardiac power, the product of cardiac index and mean arterial pressure, is a useful prognostic indicator in chronic heart failure.¹⁷ Acute heart failure patients with very high SVR and reduced CO have high cardiac power indices, in contrast to most shock patients, who have low cardiac power. In both the SHOCK trial and the SHOCK registry, cardiac power was the hemodynamic variable most strongly associated with mortality.¹⁸ A small subset of patients in the SHOCK registry was clinically diagnosed with CS without hypotension, based on systemic hypoperfusion, low CO, and elevated ventricular filling pressures. In these patients, blood pressure was maintained by elevated SVR.¹⁴ Their in-hospital mortality rate (although high at 43%) was lower than the rate of those patients with classic hypotensive shock (66%), despite the 2 groups having the same LVEF (34%), cardiac index (1.9 L/min per m²), and pulmonary capillary wedge pressure (25 mm Hg). The ability to vasoconstrict vascular beds that supply nonvital organs is an important compensatory response to a reduction in CO. Vasodilators (endogenous and exogenous) interfere with this critical response, which is needed to maintain flow to the cerebral and coronary circulations. Cardiac power is also prognostically important because it reflects myocardial reserve adequate to generate flow, albeit reduced, in the face of high resistance.

A clinically overt systemic inflammatory response syndrome as evidenced by fever, elevated white blood cell count, and low SVR, was observed in many patients with confirmed shock complicating acute MI in the randomized SHOCK trial. These findings often led to a secondary clinical diagnosis of suspected sepsis. However, the low SVR despite vasopressors was documented at shock onset, days before sepsis was suspected.¹⁹

The classic notion that CS develops when 40% of the LV is irreversibly damaged is inconsistent with the following observations:

(1) survival of 50% of patients who undergo early revascularization,

(2) evidence of improved EF in some patients following revascularization,¹¹ and

(3) New York Heart Association CHF class I for 58% of patients after shock.⁴

Resolution of severe ischemia and/or neurohormonal-inflammatory abnormalities explain the complete reversibility of the shock state in some patients. The wide variation in EF, LV size, and SVR in the SHOCK trial suggests that the pathophysiology of shock varies among patients.

	A New Paradigm

Top Introduction Classic Shock Paradigm Observations That Challenge the... A New Paradigm Effects of High Levels... Beneficial Effects of Inhibiting... Current Recommendations References

 
A systemic inflammatory response syndrome occurs in the setting of a number of noninfectious, major systemic insults, including trauma, cardiopulmonary bypass, pancreatitis, and burns.^20,21 Patients with large MIs often have elevation of body temperature, white blood cell count, complement, interleukins, C-reactive protein, and other inflammatory markers. NO, synthesized at low levels by endothelial and myocardial cell endothelial nitric oxide (eNOS), is a cardioprotective molecule.^22,23 In contrast, many cell types express iNOS at pathological levels after trauma or exposure to inflammatory mediators (ie, bacterial lipopolysaccharide, tumor necrosis factor-, and interleukin-1).²⁴ Such expression may lead to toxic levels of NO and the cytotoxic NO-derived species, peroxynitrite, formed by reaction with superoxide. In experimental models, high iNOS and NO levels are seen after MI and subsequent reperfusion.²⁵ Release of cytokines by the heart after MI has been documented in patients. These levels markedly increase after primary PCI in acute MI patients but not in control patients.²⁶ This suggests that in patients post-MI, activation of inflammatory cytokines leads to high levels of iNOS, NO, and peroxynitrite, all of which have multiple deleterious effects.

	Effects of High Levels of NO and NO-Derived Species (eg, Peroxynitrite)

Top Introduction Classic Shock Paradigm Observations That Challenge the... A New Paradigm Effects of High Levels... Beneficial Effects of Inhibiting... Current Recommendations References

 

• Direct inhibition of myocardial contractility
  
• Suppression of mitochondrial respiration in nonischemic myocardium
  
• Effects on glucose metabolism
  
• Proinflammatory effects
  
• Reduced catecholamine responsivity
  
• Induction of systemic vasodilation
  

The mechanism of the detrimental effect of high NO levels is unclear, but it may result from a direct effect of NO on myocardial contractility by uncoupling of calcium metabolism,^27,28 through effects on glucose metabolism,²⁷ or through ß-adrenergic responsivity.²⁹ High levels of iNOS are associated with LV dysfunction and higher mortality in mice with MIs.^30,31 In animal models, NO production by iNOS is deleterious during ischemia-reperfusion.^27,28 Induced iNOS expression and high NO levels during ischemia may mediate myocardial stunning. Furthermore, stimulation of iNOS expression by interleukins could explain the observation of new or worsening hypotension after primary PCI in some patients.

A marked variability in the responsiveness of the inflammatory system has been reported, supporting the concept that systemic inflammation may play a large role in some patients but not in others in the genesis and persistence of shock. Liuzzo et al³² reported an enhanced inflammatory response to PCI in patients with severe unstable angina that was highly variable and related to baseline, pre-PCI levels of interleukin-6 and C-reactive protein. In patients with acute coronary syndrome, elevated inflammatory markers, including white blood cell count and C-reactive protein, are independently associated with mortality.³³

	Beneficial Effects of Inhibiting Inflammatory Mediators and iNOS

Top Introduction Classic Shock Paradigm Observations That Challenge the... A New Paradigm Effects of High Levels... Beneficial Effects of Inhibiting... Current Recommendations References

 
Experimentally, iNOS knockout mice were shown to survive MI better than wild-type mice.^31,34 In ischemia-reperfusion models, inhibition of NO synthase appears to have favorable metabolic, antistunning, and coronary blood flow effects.^27,28 Cotter and colleagues³⁵ administered a non–isoform-specific NOS inhibitor, N^G-monomethyl-L-arginine (L-NMMA), to 11 patients with persistent shock despite vasopressors, intra-aortic balloon pump, and PCI. Urine output and blood pressure increased markedly, and 72% survived to 30 days. Cotter et al³⁶ subsequently reported a reduction in 30-day mortality from 67% to 27% with a similar NOS inhibitor, N^G-nitro-L-arginine methyl ester, in a small randomized trial of 30 patients.

Inhibition of the complement cascade at the C5 level results in, among other effects, a reduction of the excess iNOS response to ischemia and reperfusion and could theoretically inhibit the genesis of shock. Preliminary results of the COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) study demonstrate that inhibition of C5 was associated with lower rates of shock and death in high-risk patients undergoing primary PCI, despite an absence of effect on infarct size.³⁷

	Current Recommendations

Top Introduction Classic Shock Paradigm Observations That Challenge the... A New Paradigm Effects of High Levels... Beneficial Effects of Inhibiting... Current Recommendations References

 
In the randomized SHOCK trial, a strategy of early revascularization resulted in 132 lives saved at 1 year per 1000 patients treated as compared with initial medical therapy followed by no or late revascularization as clinically determined.⁴ This magnitude of benefit is comparable to that of CABG versus medical therapy for patients with left main coronary stenoses. Recommended selection of initial reperfusion for CS is outlined in Figure 2. Most patients in the SHOCK trial had severe multivessel disease, and of those revascularized in the early revascularization group of the SHOCK trial, 40% underwent CABG. This is in marked contrast to the low and decreasing rate of CABG for shock in the National Registry of Myocardial Infarction (NRMI).³⁸

View larger version (40K): [in this window] [in a new window]   Figure 2. Recommendations for initial reperfusion therapy when CS complicates acute MI. Early mechanical revascularization with PCI or CABG is strongly recommended for suitable candidates <75 years of age and for selected elderly patients (see text). Eighty-five percent of shock cases are diagnosed after initial therapy for acute MI, but most patients develop shock within 24 hours. Intra-aortic balloon pump (IABP) is recommended when shock is not quickly reversed with pharmacological therapy, as a stabilizing measure for patients who are candidates for further invasive care. Dashed lines indicate that the procedure should be performed in patients with specific indications only. Recommendations for staged CABG and multivessel PCI are discussed in the text, as are definitions of moderate and severe 3-vessel CAD. LBBB indicates left bundle-branch block.

The preferred treatment is PCI of the IRA for patients with 1- to 2-vessel coronary artery disease (CAD) and suitable lesions. Moderate 3-vessel disease, ie, 100% IRA occlusion, <90% stenosis in 2 other major vessels, or more severe lesions in second-order vessels, may be treated with PCI of the IRA and staged complete revascularization, as indicated. Glycoprotein IIb/IIIa antagonists and stents are recommended. Immediate CABG is the preferred treatment for severe 3-vessel or left main CAD. If CABG cannot be performed, single-vessel or multivessel PCI may be attempted. Distal embolization in the non–IRA territories during PCI may be disproportionately harmful in the setting of shock or recent shock. Therefore, CABG is generally preferred to PCI when revascularization of the non–IRA artery is clinically indicated in the week after shock. However, early multivessel PCI may be warranted when shock persists despite PCI of the IRA, when CABG cannot be performed.

Despite the American College of Cardiology/American Heart Association³⁹ revised guidelines class I recommendation for early revascularization in patients younger than age 75, NRMI data suggest that most patients did not receive this therapy as recently as 2001.³⁸ According to NRMI data, mortality has decreased in hospitals that perform early revascularization, but not in those that do not.³⁸ Although the small cohort of elderly patients in the SHOCK trial had a surprisingly low mortality rate in the initial medical stabilization group and did not appear to benefit from a routine strategy of early revascularization, the nearly 20% of the elderly who were clinically selected for early revascularization in the SHOCK registry appeared to have improved survival.⁴⁰ Therefore, individualized judgments must be made regarding the elderly; those with good prior functional status and less severe, early shock may be suitable candidates. For those <75 years of age, all subgroups enrolled in the SHOCK trial, based on clinical, hemodynamic, and echocardiographic characteristics,^4,11 derived benefit from early revascularization. However, patients with pre-existing severe comorbidities, life-shortening illnesses, cardiomyopathy and CHF, lack of vascular access, and anoxic brain damage are unsuitable for early revascularization and were excluded. Patients who develop shock early or late after MI (≤36 hours) and who are revascularized within 12 to 18 hours of shock onset derive benefit.^3,4 Patients with very prolonged duration of CS may be unsuitable. Because of the potential adverse effects of sympathomimetic amines, early intra-aortic balloon counterpulsation is recommended for all patients who are candidates for further therapy beyond comfort care.³⁹

The observation in the SHOCK trial and registry that only 14% and 9% of shock patients, respectively, presented to the hospital in shock, but that almost half developed it rapidly after admission, raises the concern of an iatrogenic component of shock. Negative inotropic and vasodilating agents may cause hypotension and initiate the vicious spiral of CS in patients with large MIs, multivessel disease, and marginal hemodynamic compensation.

In summary, immediate stabilization followed promptly by early revascularization is indicated when shock due to pump failure complicates acute MI. Data on ventricular function, systemic resistance, and systemic inflammatory response syndrome observed in some patients with LV failure in the SHOCK trial and registry suggest that CS complicating acute MI is often not simply due to extensive infarction and ischemia with reduced ventricular function but also involves inflammatory mediators. These mediators induce iNOS expression, increasing NO and peroxynitrite levels, resulting in further myocardial dysfunction and failure of an appropriate peripheral circulatory response. Experimental and preliminary clinical studies demonstrate improved survival when iNOS is absent or inhibited. Further investigation is needed to evaluate the inflammatory and excess iNOS component of CS, and promising new therapies that target these pathways need testing to try to reduce the persistently high mortality rate despite emergency revascularization. SHOCK-2 (SHould we inhibit nitric Oxide synthase in patients with Cardiogenic shocK?) is being designed to test an NO inhibitor, L-NMMA, in a well-powered randomized trial of patients with persistent shock despite a patent IRA.

	Acknowledgments

 
I thank Gad Cotter, MD, and Vlad Dzavik, MD, for their contributions to my understanding of the role of NO in the new paradigm and Eric Bates, MD, for his contribution to Figure 2. I thank Elliott Antman, MD, and Richard Fuchs, MD, for their excellent editing of the manuscript, and Evelyn Addo for its preparation.

	References

Top Introduction Classic Shock Paradigm Observations That Challenge the... A New Paradigm Effects of High Levels... Beneficial Effects of Inhibiting... Current Recommendations References

 

1. Goldberg RJ, Samad NA, Yarzebski J, et al. Temporal trends in cardiogenic shock complicating acute myocardial infarction. N Engl J Med. 1999; 340: 1162–1168.[Abstract/Free Full Text]
   
2. Goldberg RJ, Gore JM, Alpert JS, et al. Cardiogenic shock after acute myocardial infarction: incidence and mortality from a community-wide perspective, 1975 to 1988. N Engl J Med. 1991; 325: 1117–1122.[Abstract]
   
3. Hochman J, Sleeper L, Webb J, et al. Early revascularization in acute myocardial infarction complicated by cardiogenic shock. N Engl J Med. 1999; 341: 625–634.[Abstract/Free Full Text]
   
4. Hochman JS, Sleeper LA, White HD, et al. One-year survival following early revascularization for cardiogenic shock. JAMA. 2001; 285: 190–192.[Abstract/Free Full Text]
   
5. Jacobs AK, Sleeper LA, Forman R, et al. Cardiogenic shock caused by right ventricular infarction: a report from the SHOCK registry. J Am Coll Cardiol. 2003; 41: 1273–1279.[Abstract/Free Full Text]
   
6. Hochman JS, Buller CE, Sleeper LA, et al. Cardiogenic shock complicating acute myocardial infarction: etiologies, management and outcome: overall findings of the SHOCK Trial Registry. J Am Coll Cardiol. 2000; 36: 1063–1070.[Abstract/Free Full Text]
   
7. Webb JG, Sanborn TA, Sleeper L, et al. Percutaneous coronary intervention for cardiogenic shock in the SHOCK Trial Registry. Am Heart J. 2001; 141: 964–970.[CrossRef][Medline] [Order article via Infotrieve]
   
8. Dixon SR, Alkafri H, Chami A. Clinical predictors of in-hospital death in patients with cardiogenic shock selected to undergo early revascularization. J Am Coll Cardiol. 2002; 39 (suppl A): 808–1.Abstract.
   
9. Antman EM, Braunwald E. Acute myocardial infarction. In: Braunwald E, Fauci A, Kasper D, et al, eds. Harrison’s Principles of Internal Medicine. 15th ed. New York, NY: McGraw-Hill; 2001: 1395.
   
10. Alonso DR, Scheidt S, Post M, et al. Pathophysiology of cardiogenic shock: quantification of myocardial necrosis, clinical, pathologic and electrocardiographic correlations. Circulation. 1973; 48: 588–596.[Abstract/Free Full Text]
    
11. Picard MH, Davidoff R, Sleeper L, et al. Echocardiographic predictors of survival and response to early revascularization in cardiogenic shock. Circulation. 2003; 107: 279–284.[Abstract/Free Full Text]
    
12. Wollert KC, Drexler H. Carvedilol prospective randomized cumulative survival (COPERNICUS) trial: carvedilol as the sun and center of the ß-blocker world? Circulation. 2002; 106: 2164–2166.[Free Full Text]
    
13. Dargie HJ. Effect of carvediol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet. 2001; 357: 1385–1390.[CrossRef][Medline] [Order article via Infotrieve]
    
14. Menon V, Slater JN, White HD, et al. Acute myocardial infarction complicated by systemic hypoperfusion without hypotension: report of the SHOCK trial registry. Am J Med. 2000; 108: 374–380.[CrossRef][Medline] [Order article via Infotrieve]
    
15. Cotter G, Moshkovitz Y, Milovanov O, et al. Acute heart failure: a novel approach to its pathogenesis and treatment. Eur J Heart Fail. 2002; 4: 227–234.[CrossRef][Medline] [Order article via Infotrieve]
    
16. Cotter G, Moshkovitz Y, Kaluski E, et al. The role of cardiac power and systemic vascular resistance in the pathophysiology and diagnosis of patients with acute congestive heart failure. Eur J Heart Fail. In press.
    
17. Williams SG, Cooke GA, Wright DJ, et al. Peak exercise cardiac power output: a direct indicator of cardiac function strongly predictive of prognosis in chronic heart failure. Eur Heart J. 2001; 22: 1496–1503.[Abstract/Free Full Text]
    
18. Cotter G, Fincke R, Lowe A, et al. The predictive value of hemodynamic parameters in cardiogenic shock due to myocardial infarction: a report from the SHOCK trial registry. Eur J Heart Fail. Abstract. In press.
    
19. Kohsaka S, Menon V, Lange M, et al. High incidence of sepsis complicating cardiogenic shock following acute myocardial infarction. Circulation. 2001; 104 (suppl II): II–483.Abstract.
    
20. Hall RI, Smith MS, Rocker G. The systemic inflammatory response to cardiopulmonary bypass: pathophysiological, therapeutic, and pharmacological considerations. Anesth Analg. 1997; 85: 766–782.[CrossRef][Medline] [Order article via Infotrieve]
    
21. Davies MG, Hagen PO. Systemic inflammatory response syndrome. Br J Surg. 1997; 84: 920–935.[CrossRef][Medline] [Order article via Infotrieve]
    
22. Rubbo H, Darley-Usmar V, Freeman BA. Nitric oxide regulation of tissue-free radical injury. Chem Res Toxicol. 1996; 9: 809–820.[CrossRef][Medline] [Order article via Infotrieve]
    
23. Wink DA, Hanbauer I, Krishna MC, et al. Nitric oxide protects against cellular damage and cytotoxicity from reactive oxygen species. Proc Natl Acad Sci U S A. 1993; 90: 9813–9817.[Abstract/Free Full Text]
    
24. Li H, Forstermann U. Nitric oxide in the pathogenesis of vascular disease. J Pathol. 2000; 190: 244–254.[CrossRef][Medline] [Order article via Infotrieve]
    
25. Wildhirt SM, Dudek RR, Suzuki H, et al. Involvement of inducible nitric oxide synthase in the inflammatory process of myocardial infarction. Int J Cardiol. 1995; 50: 253–261.[CrossRef][Medline] [Order article via Infotrieve]
    
26. Neumann FJ, Ott I, Gawaz M, et al. Cardiac release of cytokines and inflammatory responses in acute myocardial infarction. Circulation. 1995; 92: 748–755.[Abstract/Free Full Text]
    
27. Depré C, Vanoverschelde J-L, Goudemant J-F, et al. Protection against ischemic injury by nonvasoactive concentrations of nitric oxide synthase inhibitors in the perfused rabbit heart. Circulation. 1995; 92: 1911–1918.[Abstract/Free Full Text]
    
28. Schulz R, Wambolt R. Inhibition of nitric oxide synthesis protects the isolated working rabbit heart from ischemia-reperfusion injury. Cardiovasc Res. 1995; 30: 432–439.[CrossRef][Medline] [Order article via Infotrieve]
    
29. Ziolo MT, Katoh H, Bers DM. Expression of inducible nitric oxide synthase depresses ß-adrenergic-stimulated calcium release from the sarcoplasmic reticulum in intact ventricular myocytes. Circulation. 2001; 104: 2961–2966.[Abstract/Free Full Text]
    
30. Ullrich R, Scherrer-Crosbie M, Bloch KD, et al. Congenital deficiency of nitric oxide synthase 2 protects against endotoxin-induced myocardial dysfunction in mice. Circulation. 2000; 102: 1440–1446.[Abstract/Free Full Text]
    
31. Feng O, Lu X, Jones DL, et al. Increased inducible nitric oxide synthase expression contributes to myocardial dysfunction and higher mortality after myocardial infarction in mice. Circulation. 2001; 104: 700–704.[Abstract/Free Full Text]
    
32. Liuzzo G, Buffon A, Biasucci LM, et al. Enhanced inflammatory response to coronary angioplasty in patients with severe unstable angina. Circulation. 1998; 98: 2370–2376.[Abstract/Free Full Text]
    
33. Sabatine MS, Morrow DA, Cannon CP, et al. Relationship between baseline white blood cell count and degree of coronary artery disease and mortality in patients with acute coronary syndromes: a TACTICS-TIMI 18 (Treat Angina with Aggrastat and determine Cost of Therapy with an Invasive or Conservative Strategy—Thrombolysis in Myocardial Infarction 18 trial) substudy. J Am Coll Cardiol. 2002; 40: 1761–1768.[Abstract/Free Full Text]
    
34. Sam F, Sawyer DB, Xie Z, et al. Mice lacking inducible nitric oxide synthase have improved left ventricular contractile function and reduced apoptotic cell death late after myocardial infarction. Circ Res. 2001; 89: 351–356.[Abstract/Free Full Text]
    
35. Cotter G, Kaluski E, Blatt A, et al. L-NMMA (a nitric oxide synthase inhibitor) is effective in the treatment of cardiogenic shock. Circulation. 2000; 101: 1358–1361.[Abstract/Free Full Text]
    
36. Cotter G, Blatt A, Kaluski E, et al. LINCS: L-NAME (a NO synthase inhibitor) in the treatment of refractory cardiogenic shock: a prospective randomized study. Eur Heart J. In press.
    
37. Granger CB, Mahaffey KW, Weaver WD, et al. Effect of pexelizumab, an anti-C5 complement antibody, as adjuctive therapy to primary percutaneous coronary intervention in acute myocardial infarction: COMplement inhibition in Myocardial infarction treated with Angioplasty. Circulation. In press.
    
38. Babaev A, Every N, Frederick P, et al. Trends in revascularization and mortality in patients with cardiogenic shock complicating acute myocardial infarction: observations from the National Registry of Myocardial Infarction. Circulation. 2002; 106 (suppl II): II–364.Abstract.
    
39. Ryan TJ, Antman EM, Brooks NH, et al. 1999 update: ACC/AHA guidelines for the management of patients with acute myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). J Am Coll Cardiol. 1999; 34: 890–911.[Free Full Text]
    
40. Dzavik V, Sleeper LA, Cocke JT, et al. Early revascularization is associated with improved survival in elderly patients with acute myocardial infarction complicated by cardiogenic shock: a report from the SHOCK trial. Eur Heart J. 2003; 24: 828–837.[Abstract/Free Full Text]
    

This article has been cited by other articles:

				S. W. Rabkin and M. Y. C. Tsang The action of nitric oxide to enhance cell survival in chick cardiomyocytes is mediated through a cGMP and ERK1/2 pathway while p38 mitogen-activated protein kinase-dependent pathways do not alter cell death Exp Physiol, July 1, 2008; 93(7): 834 - 842. [Abstract] [Full Text] [PDF]

				H. R. Reynolds and J. S. Hochman Cardiogenic Shock: Current Concepts and Improving Outcomes Circulation, February 5, 2008; 117(5): 686 - 697. [Full Text] [PDF]

				M. Enriquez-Sarano, V. T. Nkomo, and H. Michelena Principles and Practice of Echocardiography in Cardiac Surgery Card. Surg. Adult, January 1, 2008; 3(2008): 315 - 348. [Full Text]

				I. George and M. C. Oz Myocardial Revascularization after Acute Myocardial Infarction Card. Surg. Adult, January 1, 2008; 3(2008): 669 - 696. [Full Text]

				S. J. Nicholls, Z. Wang, R. Koeth, B. Levison, B. DelFraino, V. Dzavik, O. W. Griffith, D. Hathaway, J. A. Panza, S. E. Nissen, et al. Metabolic Profiling of Arginine and Nitric Oxide Pathways Predicts Hemodynamic Abnormalities and Mortality in Patients With Cardiogenic Shock After Acute Myocardial Infarction Circulation, November 13, 2007; 116(20): 2315 - 2324. [Abstract] [Full Text] [PDF]

				M. Singh, J. White, D. Hasdai, P. K. Hodgson, P. B. Berger, E. J. Topol, R. M. Califf, and D. R. Holmes Jr Long-Term Outcome and its Predictors Among Patients With ST-Segment Elevation Myocardial Infarction Complicated by Shock: Insights From the GUSTO-I Trial J. Am. Coll. Cardiol., October 30, 2007; 50(18): 1752 - 1758. [Abstract] [Full Text] [PDF]

				R. A. Harrington, J. H. Alexander, J. S. Hochman, H. R. Reynolds, V. Dzavik, and F. J. Van de Werf Tilarginine in Patients With Acute Myocardial Infarction and Cardiogenic Shock Reply JAMA, September 5, 2007; 298(9): 972 - 973. [Full Text] [PDF]

				H. Thiele, R. W. Smalling, and G. C. Schuler Percutaneous left ventricular assist devices in acute myocardial infarction complicated by cardiogenic shock Eur. Heart J., September 1, 2007; 28(17): 2057 - 2063. [Abstract] [Full Text] [PDF]

				V. Dzavik, G. Cotter, H. R. Reynolds, J. H. Alexander, K. Ramanathan, A. L. Stebbins, D. Hathaway, M. E. Farkouh, E. M. Ohman, D. A. Baran, et al. Effect of nitric oxide synthase inhibition on haemodynamics and outcome of patients with persistent cardiogenic shock complicating acute myocardial infarction: a phase II dose-ranging study Eur. Heart J., May 1, 2007; 28(9): 1109 - 1116. [Abstract] [Full Text] [PDF]

				G. Ndrepepa, A. Schomig, and A. Kastrati Lack of Benefit From Nitric Oxide Synthase Inhibition in Patients With Cardiogenic Shock: Looking for the Reasons JAMA, April 18, 2007; 297(15): 1711 - 1713. [Full Text] [PDF]

				The TRIUMPH Investigators Effect of Tilarginine Acetate in Patients With Acute Myocardial Infarction and Cardiogenic Shock: The TRIUMPH Randomized Controlled Trial JAMA, April 18, 2007; 297(15): 1657 - 1666. [Abstract] [Full Text] [PDF]

				M Pasotti, F Prati, and E Arbustini The pathology of myocardial infarction in the pre- and post-interventional era Heart, November 1, 2006; 92(11): 1552 - 1556. [Full Text] [PDF]

				B. G. Leshnower, T. G. Gleason, M. L. O'Hara, A. Pochettino, Y. J. Woo, R. J. Morris, T. J. Gardner, and M. A. Acker Safety and Efficacy of Left Ventricular Assist Device Support in Postmyocardial Infarction Cardiogenic Shock Ann. Thorac. Surg., April 1, 2006; 81(4): 1365 - 1371. [Abstract] [Full Text] [PDF]

				E. B. Manukhina, H. F. Downey, and R. T. Mallet Role of nitric oxide in cardiovascular adaptation to intermittent hypoxia. Experimental Biology and Medicine, April 1, 2006; 231(4): 343 - 365. [Abstract] [Full Text] [PDF]

				R. V. Jeger, S. M. Harkness, K. Ramanathan, C. E. Buller, M. E. Pfisterer, L. A. Sleeper, J. S. Hochman, and for the SHOCK Investigators Emergency revascularization in patients with cardiogenic shock on admission: a report from the SHOCK trial and registry Eur. Heart J., March 2, 2006; 27(6): 664 - 670. [Abstract] [Full Text] [PDF]

				S. P. Schulman, L. C. Becker, D. A. Kass, H. C. Champion, M. L. Terrin, S. Forman, K. V. Ernst, M. D. Kelemen, S. N. Townsend, A. Capriotti, et al. L-Arginine Therapy in Acute Myocardial Infarction: The Vascular Interaction With Age in Myocardial Infarction (VINTAGE MI) Randomized Clinical Trial JAMA, January 4, 2006; 295(1): 58 - 64. [Abstract] [Full Text] [PDF]

				P. Theroux, P. W. Armstrong, K. W. Mahaffey, J. S. Hochman, K. J. Malloy, S. Rollins, J. C. Nicolau, J. Lavoie, T. M. Luong, J. Burchenal, et al. Prognostic significance of blood markers of inflammation in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty and effects of pexelizumab, a C5 inhibitor: a substudy of the COMMA trial Eur. Heart J., October 1, 2005; 26(19): 1964 - 1970. [Abstract] [Full Text] [PDF]

				S. Kohsaka, V. Menon, A. M. Lowe, M. Lange, V. Dzavik, L. A. Sleeper, J. S. Hochman, and for the SHOCK Investigators Systemic Inflammatory Response Syndrome After Acute Myocardial Infarction Complicated by Cardiogenic Shock Arch Intern Med, July 25, 2005; 165(14): 1643 - 1650. [Abstract] [Full Text] [PDF]

				D. Mancini and D. Burkhoff Mechanical Device-Based Methods of Managing and Treating Heart Failure Circulation, July 19, 2005; 112(3): 438 - 448. [Abstract] [Full Text] [PDF]

				C. S. Duvernoy and E. R. Bates Management of Cardiogenic Shock Attributable to Acute Myocardial Infarction in the Reperfusion Era J Intensive Care Med, July 1, 2005; 20(4): 188 - 198. [Abstract] [PDF]

				H. Thiele, P. Sick, E. Boudriot, K.-W. Diederich, R. Hambrecht, J. Niebauer, and G. Schuler Randomized comparison of intra-aortic balloon support with a percutaneous left ventricular assist device in patients with revascularized acute myocardial infarction complicated by cardiogenic shock Eur. Heart J., July 1, 2005; 26(13): 1276 - 1283. [Abstract] [Full Text] [PDF]

				P. Libby and P. Theroux Pathophysiology of Coronary Artery Disease Circulation, June 28, 2005; 111(25): 3481 - 3488. [Abstract] [Full Text] [PDF]

				A G C Sutton, P Finn, J A Hall, A A Harcombe, R A Wright, and M A de Belder Predictors of outcome after percutaneous treatment for cardiogenic shock Heart, March 1, 2005; 91(3): 339 - 344. [Abstract] [Full Text] [PDF]

				R. Fincke, J. S. Hochman, A. M. Lowe, V. Menon, J. N. Slater, J. G. Webb, T. H. LeJemtel, G. Cotter, and SHOCK Investigators Cardiac power is the strongest hemodynamic correlate of mortality in cardiogenic shock: A report from the SHOCK trial registry J. Am. Coll. Cardiol., July 21, 2004; 44(2): 340 - 348. [Abstract] [Full Text] [PDF]

				F. J. Munoz, B. Thomas, D. De Backer, N. Lim, and J.-L. Vincent Cardiogenic Shock Chest, July 1, 2004; 126(1): 312 - 313. [Full Text] [PDF]

				C. B. Granger, K. W. Mahaffey, W. D. Weaver, P. Theroux, J. S. Hochman, T. G. Filloon, S. Rollins, T. G. Todaro, J. C. Nicolau, W. Ruzyllo, et al. Pexelizumab, an Anti-C5 Complement Antibody, as Adjunctive Therapy to Primary Percutaneous Coronary Intervention in Acute Myocardial Infarction: The COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) Trial Circulation, September 9, 2003; 108(10): 1184 - 1190. [Abstract] [Full Text] [PDF]

This Article Full Text (PDF) Alert me when this article is cited<